The GLP-1 Podcast Show - Dr. Anders Fink-Jensen: GLP-1 Therapy for Alcohol Use Disorder | Ep. 16

In this episode of The GLP-1 Podcast Show, Dr. Anders Fink-Jensen, Professor at the University of Copenhagen and a consultant psychiatrist, speaks with Areesha Moiz about the emerging role of GLP-1 receptor agonists in addiction treatment. The discussion traces the field from early clinical observations to a randomized trial evaluating semaglutide in treatment-seeking adults with alcohol use disorder and obesity. The findings showed reductions in total alcohol consumption, heavy drinking days, and craving alongside cognitive behavioral therapy. They also examine possible effects on reward, the uncertainty surrounding mechanisms in humans, dosing and weight considerations, psychiatric comorbidities, and research into other substance use disorders.

What you’ll learn: 

• Origins of GLP-1 addiction research
• Semaglutide trial findings
• Alcohol craving reduction
• Patient selection considerations
• Addiction treatment potential

Meet the guest:

Dr. Anders Fink-Jensen is a professor at the University of Copenhagen and a consultant psychiatrist. His research focuses on psychopharmacology, addiction, severe mental illness, and the clinical evaluation of GLP-1 receptor agonists in people with alcohol use disorder. Listen to Dr. Anders Fink-Jensen on The GLP-1 Podcast Show, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!